Drugs / REGN7999
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05481333 | Oct 2022 → Aug 2023 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06421636 | Sep 2024 → Dec 2026 expected | beta-thalassemia intermedia | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-03 | Regeneron Pharmaceuticals | Results Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH regeneron.com ↗
Single Ascending Doses of REGN7999, A Monoclonal Antibody Inhibitor of TMPRSS6, Increase Serum Hepcidin And Cause Deep, Sustained Reductions in Serum Iron in Healthy Human Volunteers |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-03 | Regeneron Pharmaceuticals | Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH regeneron.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN7999 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06421636 ↗ |
| Action | Inhibit | “an inhibitor of TMPRSS6” NCT06421636 ↗ |
| Route | Intravenous | “single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999” NCT05481333 ↗ |
| Route | Subcutaneous | “single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999” NCT05481333 ↗ |
| Target | TMPRSS6 | “an inhibitor of TMPRSS6” NCT06421636 ↗ |